Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention

References

• Institute of Medicine. Prospects for immunizing against respiratory syncytial virus. In: New vaccine development: establishing priorities: volume 1, diseases of importance in the United States. Washington, DC: National Academy Press, 1985:397-409
   Google Scholar
• Hall CB. Respiratory syncytial virus. In: Feigen RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. Philadelphia, PA: WB Saunders, 1987:1653-75
   Google Scholar
• Hall C. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917-28
   PubMed Web of Science ®Google Scholar
• Ruuskanen O, Ogra PL. Respiratory syncytial virus. Curr Probl Pediatr 1993;23:50-79
   PubMedGoogle Scholar
• Shay DK, Holman RC, Newman RR, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999;282:1440-6
   PubMed Web of Science ®Google Scholar
• Prober CG, Wang EE. Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answer. Pediatrics 1997;99:472-5
   PubMed Web of Science ®Google Scholar
• McLaurin KK, Leader S. Growing impact of RSV hospitalizations among infants in the US, 1997-2002. Presented at the Pediatric Academic Societies Annual Meeting; 14-17 May 2005; Washington, DC. Abstract 936
   Google Scholar
• Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med 2002;96(Suppl B):S1-7
   PubMedGoogle Scholar
• American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Long SS, et al., eds. Red Book: 2006 report of the Committee on Infectious Diseases. 27th rev edn. Elk Grove Village, IL: American Academy of Pediatrics, 2006:560-7
   Google Scholar
• Oelberg D, Reininger M, Eeckhout JV. A cost-benefit analysis of respiratory syncytial virus hyperimmune globulin (RSV-IVIG) in high-risk infants. Neonatal Intensive Care 1998;11:29-33
   Google Scholar
• Katz BZ, Lo J, Sorrentino M. Costs of respiratory syncytial virus infection at a tertiary-care children's hospital. Pharmacol Ther 2003;28:343-5
   Google Scholar
• Altman CA, Englund JA, Demmler G, et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433-8
   PubMed Web of Science ®Google Scholar
• Howard TS, Hoffman LH, Stang PE, et al. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J Pediatr 2000;137:227-32
   PubMed Web of Science ®Google Scholar
• Kohlhase K, Leader S. Impact of congenital heart disease (CHD) on RSV hospital resource use. Pediatr Res 2003;53(4[Part 2 of 2]):486A. Abstract 2743
   Google Scholar
• Ehlken B, Ihorst G, Lippert B, et al. Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany. Eur J Pediatr 2005;164:607-15
   PubMed Web of Science ®Google Scholar
• Roeckl-Wiedmann I, Liese JG, Grill E, et al. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:237-44
   PubMed Web of Science ®Google Scholar
• Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003;88:1065-9
   PubMed Web of Science ®Google Scholar
• Miedema CJ, Kors AW, Tjon A, et al. Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in the Netherlands. Pediatr Infect Dis J 2001;20:160-3
   PubMed Web of Science ®Google Scholar
• Rietveld E, De Jonge HC, Polder JJ, et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr Infect Dis J 2004;23:523-9
   PubMed Web of Science ®Google Scholar
• Langley JM, Wang EE, Law BJ, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr 1997;131(1 Pt 1):113-7
   PubMed Web of Science ®Google Scholar
• Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104(3 Pt 3):419-27
   PubMed Web of Science ®Google Scholar
• Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000;154:55-61
   PubMed Web of Science ®Google Scholar
• Elhassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006;160:1070-6
   PubMed Web of Science ®Google Scholar
• Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 2002;156:1034-41
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007;25:55-71
   PubMed Web of Science ®Google Scholar
• Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, et al. The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32--35 weeks in Spain [in Spanish]. An Pediatr (Barc) 2006;65:316-24
   PubMedGoogle Scholar
• Sampalis J. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143(5 Suppl):S150-6
   PubMed Web of Science ®Google Scholar
• Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001;85:463-8
   PubMed Web of Science ®Google Scholar
• US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999-2008, Medical Care. Series ID: SUUR0000SAM. Washington, DC: US Dept. of Labor, Bureau of Labor Statistics, 2008. Available at: http://data.bls.gov/cgi-bin/surveymost?su [Last accessed 9 June 2008]
   Google Scholar
• Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998;17:283-95
   PubMed Web of Science ®Google Scholar
• Carroll K, Gebretsadik T, Griffin MR, et al. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics 2008;122:58-64
   PubMed Web of Science ®Google Scholar
• Broughton S, Sylvester KP, Fox G, et al. Lung function in prematurely born infants after viral lower respiratory tract infections. Pediatr Infect Dis J 2007;26:1019-24
   PubMed Web of Science ®Google Scholar
• Friedrich L, Stein RT, Pitrez PM, et al. Reduced lung function in health preterm infants in the first months of life. Am J Respir Crit Care Med 2006;173:442-7
   PubMed Web of Science ®Google Scholar
• Friedrich L, Pitrez PM, Stein RT, et al. Growth rate of lung function in healthy preterm infants. Am J Respir Crit Care Med 2007;176:1269-73
   PubMed Web of Science ®Google Scholar